Retatrutide — Provider-Supervised GLP-1 / GIP / Glucagon Program

Retatrutide is a prescription-only, investigational medication that has not been approved by the FDA. Treatment is provided only after consultation and approval by a licensed healthcare provider.

Retatrutide is a triple GLP-1 / GIP / glucagon receptor agonist peptide that may be considered for certain patients as part of a physician-supervised weight-management plan. A licensed provider determines whether retatrutide is appropriate based on individual medical history and eligibility. Individual response and outcomes vary.

What your provider may discuss during consultation

• Whether triple-agonist therapy may align with your individual goals
• Effects on appetite signaling and energy balance as part of your overall plan
• Glycemic and metabolic considerations relevant to your medical history
• Lifestyle integration, adherence, and follow-up
• Monitoring schedule and laboratory work, as appropriate

Individual response varies. No specific outcome is promised. Not all patients are candidates.

How treatment is initiated

Treatment begins with a one-on-one telemedicine consultation with a licensed provider, who reviews your medical history, screens for contraindications, and determines whether retatrutide is clinically appropriate for you. Self-administration technique, if applicable, is taught by the provider after they have determined the medication is appropriate.

Frequently asked questions

How is eligibility determined?
A licensed provider determines eligibility after a comprehensive evaluation. Patients with certain conditions — including a personal or family history of medullary thyroid carcinoma, MEN-2, pancreatitis, pregnancy or breastfeeding, among others — are not candidates. Your provider will review contraindications during consultation.

How does retatrutide work?
Retatrutide acts on three pathways related to appetite signaling, glucose regulation, and energy expenditure. Mechanism information is for education only and is not a benefit claim. Your provider will explain the mechanism, potential effects, side effects, and alternatives during consultation.

How is retatrutide different from semaglutide or tirzepatide?
Semaglutide acts on one receptor (GLP-1), tirzepatide on two (GLP-1 / GIP), and retatrutide on three (GLP-1 / GIP / glucagon). Which option, if any, is appropriate for you is a clinical decision made by your provider.

How quickly will I see results?
Individual response varies. Your provider will discuss expectations during consultation. We do not promise specific timelines or outcomes.

How is it stored?
Storage instructions are reviewed by the prescribing provider or pharmacy when your medication is dispensed.

Important Information About This Treatment

Retatrutide is an investigational medication that has not been approved by the FDA for any indication. It is available only where a licensed provider determines it is appropriate and it is dispensed by a licensed pharmacy pursuant to a valid prescription. The FDA does not verify the safety, effectiveness, or quality of compounded drugs. Eligibility, dosing, and continuation are determined by a licensed provider after a clinical consultation. Booking a consultation does not mean this medication will be prescribed for you. Treatment is not appropriate for everyone.

Individual Response. Outcomes vary from patient to patient. We do not promise any specific outcome.

Reporting Adverse Events. If you experience a side effect, contact us, your prescribing provider, and FDA MedWatch at https://www.fda.gov/safety/medwatch.

Emergencies. This site and our telehealth services are not for medical emergencies. Call 911 in a medical emergency.

Self-injection with an insulin syringe. A provider will contact you to schedule a telemedicine consultation in order to train you on the self-injection technique.

A consultation is mandatory before shipping your order as part of our medical practice process. After you place your order, someone from our team will contact you to schedule the consultation.